title: Dendritic cell and cancer immune checkpoint.
abstract: Extensive research over 100 years has clarified that cancers are surely suppressed by human immune system. Unfortunately, a number of clinical trials with various approaches have fallen short of clinical application because of the lack of significant anti-tumor effect. However, recent approved immune checkpoint inhibitors, namely PD-1 and CTLA-4 blockers, provide even better prognosis than existing chemotherapy in patients with certain types of cancer. There is no doubt that immunotherapy is becoming a standard treatment as well as surgery, chemotherapy and radiotherapy. Dendritic cells express a variety of immune checkpoint molecules including one with unknown function. In addition, accumulating evidence reported that already known molecules might have alternative functions. Further investigation of this field would lead to development of more effective treatments for cancer with less adverse effects. In this short review, we introduce some immune checkpoint molecules expressed in dendritic cells from the point of view of cancer immunotherapy.
authors: Department Pathology, Sapporo Medical University School of Medicine.
authors: Terufumi
authors: T
authors: Kubo
authors: Yoshihiko
authors: Y
authors: Hirohashi
authors: Toshihiko
authors: T
authors: Torigoe
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab